NEW YORK (MarketWatch) - Merck & Co. on Friday said it revised the filing timeline for its investigational treatment in development for atherosclerosis, or MK-0524B. The Whitehouse Station, NJ-based ...
Merck MRK announced that the FDA had accepted the biologics license application (“BLA”) seeking approval for sotatercept, its novel investigational activin signaling inhibitor, as a potential ...
Merck KGaA (XTRA:MRK) is back in focus after the U.S. FDA accepted its new drug application for pimicotinib, supported by late stage trial data, alongside previously reported earnings that exceeded ...
It’s been relatively smooth sailing for AstraZeneca and Merck’s Lynparza as it has gained indications in ovarian, breast, pancreatic and prostate cancer. But on Thursday, the companies reported a snag ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results